Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Tesamorelin

Egrifta, TH9507

A synthetic growth hormone-releasing hormone analog used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy.

Quick Stats
Studies 64
Trials 24
Formula C221H366N72O67S
Clear All
Utility 4
pubmed Sep 26, 2012

Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.

Makimura. Hideo H; Feldpausch. Meghan N MN; Rope. Alison M AM; Hemphill. Linda C LC; Torriani. Marti...

In a year‑long trial, daily 2 mg tesamorelin (a growth‑hormone‑releasing factor) cut belly‑deep visceral fat, lowered triglycerides, C‑reactive protein and carotid artery thickness, while leaving blood sugar unchanged and causing no serious side effects.

Utility 4
pubmed Jun 16, 2010

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.

Falutz. Julian J; Mamputu. Jean-Claude JC; Potvin. Diane D; Moyle. Graeme G; Soulban. Graziella G; L...

Tesamorelin, a daily 2 mg injection, cuts belly fat (visceral fat) by about 15% in HIV patients on ART after 6 months, keeps the loss for a year, improves cholesterol and triglycerides, and makes people feel better about their midsection, all without hurting blood sugar.

Utility 4
pubmed 2011

Pathogenesis and treatment of HIV lipohypertrophy.

Leung. Vivien L VL; Glesby. Marshall J MJ

Tesamorelin, a drug that mimics a hormone that tells your body to release growth hormone, has been shown in studies to shrink the deep belly fat that often builds up in people with HIV, improve cholesterol numbers, and cause only minor changes in blood sugar. However, the best dose and how long to take it aren’t fully worked out yet, and we still don’t know if it will lower heart‑disease risk over the long run.

Utility 4
pubmed 2010

Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection.

Moyle. Graeme G; Moutschen. Michel M; Martínez. Esteban E; Domingo. Pere P; Guaraldi. Giovanni...

The study shows that the growth‑hormone‑releasing hormone analog tesamorelin can cut belly‑fat (visceral fat) in about 3‑6 months, but the effect disappears if you stop taking it. It’s one of several options (like metformin or switching HIV meds) that can help lower the risky fat that often builds up in people with HIV.

Utility 4
pubmed Jun 18, 2013

Growth hormone in the aging male.

Sattler. Fred R FR

In older men, growth hormone levels drop, leading to loss of muscle, more belly fat, and slower thinking. Giving growth hormone can add about 2 kg of lean muscle and cut fat, but it doesn’t clearly make you stronger or feel better. A drug called tesamorelin, which tricks the body into releasing its own growth hormone, can lower belly fat, improve blood vessel health, lower triglycerides, and boost cognition in seniors.

Utility 4
pubmed Jun 20, 2024

Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.

Russo. Samuel C SC; Ockene. Mollie W MW; Arpante. Allison K AK; Johnson. Julia E JE; Lee. Hang H; To...

In people living with HIV who are taking modern integrase inhibitor drugs, a daily 2 mg dose of the peptide tesamorelin for a year significantly shrank belly fat, reduced liver fat, and improved overall body‑fat distribution without worsening blood sugar control.

Utility 4
pubmed 2010

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.

Falutz. Julian J; Potvin. Diane D; Mamputu. Jean-Claude JC; Assaad. Hani H; Zoltowska. Monika M; Mic...

In a 12‑month trial with HIV‑positive adults on antiretroviral therapy, daily injections of 2 mg tesamorelin cut visceral belly fat by about 11% after six months and roughly 18% after a year, without raising blood sugar or causing major side effects. Participants also felt better about their midsection shape.

Utility 4
pubmed 2012

Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.

Baker. Laura D LD; Barsness. Suzanne M SM; Borson. Soo S; Merriam. George R GR; Friedman. Seth D SD;...

A 20‑week trial gave adults aged 55‑87 a daily night‑time injection of 1 mg tesamorelin (a synthetic growth‑hormone‑releasing hormone). Both people with mild cognitive impairment and healthy seniors showed modest but significant improvements in thinking skills, especially executive function, and also lost a few percent body fat. Side effects were mild and occurred in about two‑thirds of the treated group.

Utility 4
pubmed Oct 13, 2010

Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men.

Stanley. Takara L TL; Chen. Cindy Y CY; Branch. Karen L KL; Makimura. Hideo H; Grinspoon. Steven K S...

A two‑week daily injection of tesamorelin (2 mg under the skin) in middle‑aged healthy men boosted both the overall amount and the pulse‑like bursts of growth hormone overnight, and raised IGF‑1 levels, while leaving the body’s ability to take up glucose unchanged. This suggests you can raise GH short‑term without immediately harming insulin sensitivity.

Utility 3
pubmed Jul 15, 2021

Tesamorelin improves fat quality independent of changes in fat quantity.

Lake. Jordan E JE; La. Kristen K; Erlandson. Kristine M KM; Adrian. Stefan S; Yenokyan. Gayane G; Sc...

Tesamorelin, a drug that mimics a hormone that tells the body to release growth hormone, not only shrinks belly fat in people with HIV but also makes the remaining fat denser, which means the fat cells are smaller and healthier. This improvement in fat quality happens even if the total amount of fat doesn’t change much.

Utility 3
pubmed Aug 20, 2020

Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.

Fourman. Lindsay T LT; Billingsley. James M JM; Agyapong. George G; Ho Sui. Shannan J SJ; Feldpausch...

Tesamorelin, a drug that mimics growth‑hormone‑releasing hormone, was shown to cut liver fat and stop scarring in people with HIV who have fatty liver disease, and it also shifts liver gene activity toward better energy use and less inflammation.

Utility 3
pubmed Jun 15, 2017

Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.

Clemmons. David R DR; Miller. Sam S; Mamputu. Jean-Claude JC

A 12‑week study gave people with type 2 diabetes either a placebo or tesamorelin (1 mg or 2 mg daily). The drug didn’t change blood sugar, insulin response, or overall diabetes control, but the higher dose lowered total and non‑HDL cholesterol a bit. No one had to stop because their diabetes got worse.

Utility 3
pubmed Jan 31, 2012

Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.

Spooner. Linda M LM; Olin. Jacqueline L JL

Tesamorelin, a drug that mimics a natural hormone, was shown in two big studies to shrink belly fat and the dangerous fat around organs in people with HIV who have a condition called lipodystrophy. The shrinkage lasted up to a year and people felt better about their bodies, without hurting blood sugar or cholesterol. However, it’s pricey, only approved for HIV‑related fat issues, and we don’t yet know the very long‑term safety or how well it works for folks without HIV.

Utility 3
pubmed Jun 28, 2012

How to diagnose a lipodystrophy syndrome.

Vantyghem. Marie-Christine MC; Balavoine. Anne-Sophie AS; Douillard. Claire C; Defrance. Fréd&#...

The abstract reviews many rare fat‑loss diseases and notes that while leptin can help genetic forms, the drug tesamorelin (a growth‑hormone‑releasing hormone analog) has been shown to improve the metabolic problems seen in HIV‑related lipodystrophy, such as excess belly fat and insulin resistance.

Utility 3
pubmed Oct 11, 2019

Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.

Stanley. Takara L TL; Fourman. Lindsay T LT; Feldpausch. Meghan N MN; Purdy. Julia J; Zheng. Isabel...

In a 12‑month trial, daily 2 mg tesamorelin significantly cut liver fat in people with HIV who also had fatty liver disease, without worsening blood sugar, though it caused more mild injection‑site irritation. About a third of treated participants got their liver fat back to normal levels, compared with only a few on placebo.

Utility 3
pubmed Dec 20, 2013

The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

Makimura. Hideo H; Murphy. Caitlin A CA; Feldpausch. Meghan N MN; Grinspoon. Steven K SK

In a 12‑month trial, giving the peptide tesamorelin to obese adults with low growth hormone raised their IGF‑1 levels a lot and this boost was linked to faster recovery of phosphocreatine after exercise, a sign that their mitochondria worked better. The link stayed strong even after accounting for age, sex, body fat and insulin sensitivity.

Utility 3
pubmed Jun 1, 2011

Tesamorelin: a novel therapeutic option for HIV/HAART-associated increased visceral adipose tissue.

Falutz. Julian J

Tesamorelin is a lab-made hormone that helps the body release growth hormone naturally. In people with HIV on treatment, it cuts belly fat, improves bad cholesterol numbers, and usually doesn’t mess up blood sugar. The fat comes back quickly if you stop the drug, and we still don’t know the long‑term heart benefits or how to keep the results after stopping.

Utility 3
pubmed Jan 25, 2011

Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials.

Sivakumar. T T; Mechanic. Oj O; Fehmie. D A DA; Paul. Bt B

A review of ten studies shows that drugs that boost the growth‑hormone system, like tesamorelin, can shrink the dangerous belly‑fat (visceral fat) and add a little muscle mass in people with HIV‑related fat problems, but they don’t change the fat under the skin and can cause joint aches and swelling.

Utility 3
pubmed Oct 7, 2017

Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.

Braun. Laurie R LR; Feldpausch. Meghan N MN; Czerwonka. Natalia N; Torriani. Martin M; Grinspoon. St...

In a study of HIV‑positive adults, daily tesamorelin (2 mg) for six months lowered liver fat and also reduced the hormone FGF21, which usually rises when the liver is fatty. The drop in FGF21 tracked with improvements in liver health markers, showing that tesamorelin’s liver‑fat‑cutting effect isn’t because it raises FGF21. This suggests growth‑hormone‑boosting can improve liver health through other pathways.

Utility 3
pubmed Aug 1, 2008

Approach to the human immunodeficiency virus-infected patient with lipodystrophy.

Brown. Todd T TT

HIV patients on modern drug combos often get weird fat changes – losing fat under the skin and gaining it around the belly – plus bad cholesterol and insulin issues. These problems come from the meds, the virus, and personal factors. Changing to gentler HIV drugs, diet/exercise or surgery, and new hormones that act on the growth‑hormone system can help, while some diabetes drugs (like thiazolidinediones) might be better than metformin for those losing sub‑cutaneous fat.